Microbix Biosystems Inc. Stock price

Equities

MBX

CA59501P1045

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:51:07 2024-03-27 pm EDT 5-day change 1st Jan Change
0.375 CAD -2.60% Intraday chart for Microbix Biosystems Inc. 0.00% -3.85%
Sales 2024 * 18.59M 25.26M Sales 2025 * 21.32M 28.97M Capitalization 37.93M 51.53M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 2.04 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.78 x
P/E ratio 2024 *
18.8 x
P/E ratio 2025 *
18.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.93%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Microbix Biosystems Inc.

1 day-2.60%
Current month-5.06%
1 month-5.06%
6 months+17.19%
Current year-3.85%
More quotes
1 week
0.37
Extreme 0.365
0.39
1 month
0.37
Extreme 0.365
0.41
Current year
0.37
Extreme 0.365
0.45
1 year
0.23
Extreme 0.23
0.47
3 years
0.23
Extreme 0.23
0.87
5 years
0.17
Extreme 0.17
0.87
10 years
0.16
Extreme 0.16
0.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 12-03-07
Director of Finance/CFO - 16-10-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 90-09-30
Director/Board Member - 05-12-05
Chief Executive Officer - 12-03-07
More insiders
Date Price Change Volume
24-03-27 0.375 -2.60% 97,050
24-03-26 0.385 +2.67% 4,970
24-03-25 0.375 +1.35% 9,300
24-03-22 0.37 -2.63% 397,500
24-03-21 0.38 +1.33% 40,000

Delayed Quote Toronto S.E., March 27, 2024 at 03:51 pm EDT

More quotes
Microbix Biosystems Inc. is a Canada-based life science company, which develops and commercializes biological and technological solutions for human health and wellbeing. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, mainly antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. It operates through two segments: the development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and the development and commercialization of products or technologies such as Kinlytic. Its Kinlyti urokinase is a biologic thrombolytic drug used to treat blood clots.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.375 CAD
Average target price
0.8 CAD
Spread / Average Target
+113.33%
Consensus
  1. Stock
  2. Equities
  3. Stock Microbix Biosystems Inc. - Toronto S.E.